Loading...
•
Mar 31, 2020
Kiniksa Q1 2020 Earnings Report
Kiniksa advanced its clinical-stage pipeline despite the COVID-19 pandemic.
Key Takeaways
Kiniksa reported first quarter 2020 financial results, highlighting the continued advancement of its clinical-stage pipeline despite the COVID-19 pandemic. The company's cash runway is projected to extend into the second half of 2021, and clinical timelines remain on track. Evaluation of mavrilimumab in COVID-19 pneumonia and hyperinflammation is progressing, with further clinical data expected from vixarelimab in the first half of 2020 and data from rilonacept, mavrilimumab, and KPL-404 in the second half of the year.
Kiniksa continued to advance its clinical-stage pipeline in the first quarter despite the COVID-19 pandemic.
The company's projected cash runway extends into the second half of 2021.
Clinical timelines remain on track.
Evaluation of mavrilimumab in COVID-19 pneumonia and hyperinflammation is progressing.
Forward Guidance
Kiniksa expects further clinical data from vixarelimab in the first half of 2020 as well as data from rilonacept, mavrilimumab and KPL-404 in the second half of the year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...